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Abstract 40 
Background. While the burden of influenza is often considered in the context of historical pandemics and 
the threat of a future pandemic, every year a substantial burden occurs due to lower respiratory infections 
(LRIs), other respiratory conditions (like chronic obstructive pulmonary disease), and cardiovascular 
conditions that are attributable to seasonal influenza. The Global Burden of Disease Study 2017 (GBD 
2017) is a systematic, scientific effort to quantify the health-loss associated with a comprehensive set of 45 
diseases and disabilities. This paper focuses on LRIs which can be attributed to influenza.  
Methods. We modelled the LRI incidence, hospitalisations, and mortality attributable to influenza for 
every country and select subnational locations by age and year from 1990-2017 as part of GBD 2017. We 
used a counterfactual approach that first estimated the LRI incidence, hospitalisations, and mortality and 
then attributed a fraction of those outcomes to influenza.  50 
Findings. Influenza LRI was responsible for an estimated 144,505 deaths among all ages in 2017 (95% 
Uncertainty Interval [UI] 98,922-200,205). The influenza LRI mortality rate was highest among adults 
over 70 (16.4 deaths per 100,000, 95% UI 11.6-21.9) and the highest rate among all ages was in Eastern 
Europe (5·0 per 100,000, 95% UI 3·6-6.5). We estimated that influenza LRI accounted for 9,458,902 LRI 
hospitalisations (95% UI 3,708,873-22,934,779) and 81,535,737 hospital-days (95% UI 24,330,208-55 
259,851,048). We estimated that 11.5% of LRI episodes were attributable to influenza (95% UI 10.0-
12.9%), accounting for 54,480,725 LRI episodes (95% UI 38,465,002-73,864,037), and 8,172,109 severe 
LRI episodes (5,000,450-13,295,527).  
Conclusion. This comprehensive assessment of the burden of influenza LRI highlights the substantial 
annual impact on global health. While preparedness planning will be important for potential pandemics, it 60 
is important to not overlook the ongoing health-loss due to seasonal influenza LRI, including vaccine use. 
Efforts to improve influenza prevention measures are needed. 
Funding. Funding was provided by the Bill & Melinda Gates Foundation. 
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Research in context 
Evidence before the study. The burden of influenza has frequently been described in geographic1 or age-
specific2 subpopulations with a number of studies reporting on pandemic H1N13 or syndromic definitions 
of influenza, such as among influenza-like illness.4 There have been several studies that sought to 
describe mortality and morbidity associated with influenza, including a recent publication led by the 70 
United States Centers for Disease Control and the World Health Organization that estimated 298,243-
645,832 seasonal influenza-associated respiratory deaths globally in 2015.5 Previous iterations of the 
Global Burden of Disease study (GBD) reported influenza-attributable lower respiratory infection (LRI) 
mortality focusing on the global level and most recently estimated 58,193 deaths (95% Uncertainty 
Interval 43,953-74,175) in 2016.6,7 An analysis for a comprehensive description of influenza LRIs that 75 
covers a spectrum of disease for every age, geography, and over time has not been previously undertaken.  
Added value of this study. This study sought to build on previous GBD results to produce estimates of 
the influenza-attributable LRI burden spanning incidence, hospitalisations, and deaths for every country 
globally, for both sexes, for all ages, and between 1990-2017. To the best of our knowledge, no other 
study has produced estimates at such specific demographic categories. We leverage the statistical 80 
methodology developed for the GBD to produce internally consistent estimates of LRI morbidity and 
mortality, and applied a counterfactual strategy to determine the fraction of LRI burden that is directly 
caused by influenza. The strength of this methodology is that the results are interpretable as a preventable 
burden if influenza transmission were reduced or eliminated. Such findings provide detailed evidence 
about where influenza LRI burden is greatest by age and geography and about the potential health impact 85 
of efforts to reduce influenza transmission. 
Implications. Our estimates of influenza LRI suggest that the burden is not uniform across space or by 
age and that locations or age groups with the highest underlying rate of LRI have the highest influenza 
LRI burden. Interventions that affect influenza transmission, such as vaccination, should be combined 
with interventions that reduce LRI risk, such as improving air quality, to reduce the overall burden of 90 
influenza LRI.  
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Introduction  
One hundred years ago, in 1918, an influenza pandemic killed an estimated 20-50 million people,8–10 95 
more than the number that died in World War 1. Today, seasonal influenza remains a substantial 
contributor to the growing number of lower respiratory infection (LRI) cases across the globe. 6  There is 
ongoing interest and research in understanding the pandemic potential of influenza.11–13 Such efforts have 
focused on understanding risk factors predictive of pandemic potential, modelling disease transmission to 
inform preparedness,12 and identifying strategies to interrupt or mitigate pandemics.14 Still, the sum of 100 
seasonal influenza deaths in the last 100 years likely exceeds deaths due to influenza pandemics, and 
seasonal influenza is responsible for substantial mortality, disability, and economic disruption. 
Appropriate steps to decrease this burden requires timely and reliable estimates of the full spectrum of 
disease. 
The construction of an influenza disease burden pyramid would include metrics describing the spectrum 105 
of disease from incidence of moderate and severe LRIs, hospitalisations, and deaths (Figure 1). In 
contrast, a transmission pyramid may also include asymptomatic infections, which, by definition, do not 
have a disease burden but may be crucial to understand influenza transmission dynamics. This 
conceptualisation may allow public health officials, health care providers, and policy-makers to use 
available data to focus on any point of the pyramid and develop a comprehensive sense of influenza 110 
burden. Yet determining the burden of influenza LRI is difficult in many settings for a number of reasons 
including diagnosis of LRI, detection of influenza, and data availability. Further, there is a relative dearth 
of information available on the burden of influenza as an aetiology of LRI,15 and a full perspective of the 
health-loss associated with influenza LRI at the population level is important for understanding burden 
and developing surveillance and intervention programs.  115 
The Global Burden of Disease study 2017 (GBD) is a systematic, scientific effort to produce 
comprehensive and comparable estimates of the burden of disease across causes of death and disability. 
Here, we seek to quantify the influenza LRI burden and overcome some of these challenges using a 
counterfactual approach to estimating LRIs caused by influenza and build on previous descriptions of LRI 
in the GBD.16,6 LRIs are the leading cause of infectious disease mortality, responsible for more deaths 120 
globally than tuberculosis and HIV combined. They were responsible for more than 2,500,000 deaths, and 
were the 5th leading incident infectious disease (336,461,645 episodes [95% Uncertainty Interval 
313,084,637-361,621,709]) in 2016.6 Within the GBD framework, influenza is considered a causal 
aetiology only for LRIs and it is estimated as a subset of the overall LRI burden. In this manuscript, we 
describe the global influenza LRI incidence, influenza LRI hospitalisation rates, and number of deaths 125 
due to influenza LRI across time, geography, and by age group.  
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Methods 
Influenza in the GBD is considered as one of the causative aetiologies of LRI. A comprehensive 
description of LRI modelling has been described elsewhere, and so these methods focus on specific 130 
methodology for influenza attribution in GBD 2017.6 This study complies with the Guidelines for 
Accurate and Transparent Health Estimates Reporting (GATHER) statement17 (appendix table 1).  
LRIs were defined as clinician-diagnosed pneumonia or bronchiolitis.6 There is evidence of a causal 
association between influenza and LRIs among children under 5 when it is detected by RT-PCR from 
respiratory samples.18 Based on these data18 we estimated a population attributable fraction (PAF) of LRI 135 
episodes, hospitalisations, and deaths that were caused by influenza. This approach is a counterfactual 
analysis to determine the contribution of influenza to LRI. In this analysis, the counterfactual that is being 
estimated is the burden of LRI that would exist in the absence of influenza, in other words, the burden of 
LRI causally attributable to influenza. The attribution was based on the exposure and the risk of the 
outcome.   140 
We updated a systematic review of scientific literature for the proportion of LRI that tested positive for 
influenza to include all data from GBD 2016 and from studies published between January 1, 1990 and 
May 26, 2017. The search string is provided in the Appendix (Appendix page 2). Inclusion criteria were 
studies that had a sample size of at least 100 people to avoid potential biases associated with having small 
denominators (consistent with other aetiologies in GBD 2017), studies that were at least one year in 145 
duration to limit seasonal detection bias, and studies that used a case definition of LRI, pneumonia, or 
bronchiolitis. During our new literature review we identified 595 studies, of which 75 met our inclusion 
criteria and were extracted which were added to the 153 existing data sources that were used in GBD 
2016 and extracted using the same inclusion and exclusion criteria. We excluded studies that described 
2009 pandemic H1N1 influenza solely and studies that used influenza-like illness as the outcome 150 
definition. We did not include surveillance or administrative data because they do not typically report the 
proportion of LRI positive for influenza and because they are prone to reporting and testing biases.  
Specifically, we sought to model the frequency of detection of influenza in LRI episodes based on a 
reverse transcription polymerase chain reaction (RT-PCR) reference case definition. The frequency of 
detection is a modeled value with variation in age, sex, year, and geography from our model and based on 155 
the distributions of the input data. In this model, we estimated the relative frequency of detection in 
hospitalised compared to non-hospitalised populations and assumed that this was a proxy for fatal LRI 
episodes. In contrast to a categorical approach, which would stop at this point, the counterfactual 
approach required quantifying the relative risk of LRI given the evidence of influenza in the nasal or 
oropharynx for which we used odds ratios from a systematic review and meta-analysis among children 160 
under 5.18 In the absence of available and reliable results in older children and adults, we assumed that 
this association was constant across age groups. 
We estimated three related PAFs for non-mutually exclusive influenza LRI categories: a non-fatal PAF, a 
hospitalisation PAF, and a fatal PAF. The non-fatal attribution is the simplest and was defined as 
𝑃𝐴𝐹 = 𝑭𝒓𝒆𝒒𝒖𝒆𝒏𝒄𝒚 (𝒑𝒓𝒐𝒑𝒐𝒓𝒕𝒊𝒐𝒏) ∗ (𝟏 −
𝟏
𝑶𝑹
) 165 
Where 𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 is the modeled proportion of LRI episodes that test positive for influenza by PCR and 
varies by age, sex, year, and geography and OR is the odds ratio of an LRI episode given the presence of 
influenza in a respiratory tract sample (5.10, 95% Confidence Interval 3.19 to 8.14). 18 To account for the 
previously described frequency of influenza detection in hospitalised compared to non-hospitalised LRI 
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episodes, we applied a constant scalar to determine the PAF for LRI hospitalisations which was 170 
determined by comparing the mean frequency of influenza detection in hospitalised compared to non-
hospitalised sample populations in the proportion data from our literature review (Hospital scalar).  
PAF Hospitalisations = 𝑭𝒓𝒆𝒒𝒖𝒆𝒏𝒄𝒚 (𝒑𝒓𝒐𝒑𝒐𝒓𝒕𝒊𝒐𝒏) ∗ (𝟏 −
𝟏
𝑶𝑹
) ∗ 𝑯𝒐𝒔𝒑𝒊𝒕𝒂𝒍 𝒔𝒄𝒂𝒍𝒂𝒓  
Finally, to account for the relative difference in the risk of mortality between bacterial and viral causes of 
LRIs, we modelled the ratio in case fatality of viral-to-bacterial ICD-coded hospital admissions 175 
(Appendix page 22). Hospital data from high and low-income countries were used in this analysis and 
we estimated an age-specific curve for this relationship (Appendix Table 3). This scalar was applied to 
determine the attribution of influenza for fatal LRI outcomes (Fatality scalar). 
PAF Fatal = 𝑭𝒓𝒆𝒒𝒖𝒆𝒏𝒄𝒚 (𝒑𝒓𝒐𝒑𝒐𝒓𝒕𝒊𝒐𝒏) ∗ (𝟏 −
𝟏
𝑶𝑹
) ∗ 𝑯𝒐𝒔𝒑𝒊𝒕𝒂𝒍 𝑺𝒄𝒂𝒍𝒂𝒓 ∗ 𝑭𝒂𝒕𝒂𝒍𝒊𝒕𝒚 𝑺𝒄𝒂𝒍𝒂𝒓   
The final number of LRI episodes, hospitalisations, and deaths attributable to influenza was the product of 180 
the relevant PAF and the overall number of episodes, hospitalisations, and deaths for each country, year, 
age, and sex. A description of the modeling strategy for LRI mortality, episodes, and hospitalisations 
follows and were modeled independently of influenza attributable fractions. 
The mortality due to LRIs was modelled using a Bayesian predictive ensemble modelling tool developed 
for the GBD study called the Cause of Death Ensemble Model (CODEm) which is described in detail 185 
elsewhere.7,19 In brief, CODEm uses a covariate selection algorithm to produce a wide array of sub-
models which are evaluated based on their out-of-sample predictive validity. The best performing models 
then contribute relatively more to a final ensemble model of LRI mortality. The input data for this model 
are vital registration data, verbal autopsy studies, and surveillance system records (GHDx). The 
predictive validity of this model was evaluated using out-of-sample statistics and we identified the best 190 
performing model as the one with the best out-of-sample values.  
The incidence of all LRI episodes was modelled in a Bayesian meta-regression tool developed for the 
GBD study called DisMod-MR 2·1 (DisMod).20 DisMod is designed to incorporate all available 
epidemiological data, standardise them so that they are comparable, and develop age, sex, year, and 
geography specific estimates of disease burden. Data for this model primarily come from population-195 
representative surveys, inpatient and outpatient healthcare utilisation records, and scientific literature. 
LRIs in GBD are defined as either moderate or severe and the proportion of severe LRI episodes was 
determined by a meta-analysis of the incidence of severe, defined as either requiring inpatient admission, 
requiring oxygen therapy, or meeting the Integrated Management of Childhood Infections definition of 
severe pneumonia, compared to non-severe LRI from studies that reported the incidence of both.6 Severe 200 
influenza LRI and hsopitalised influenza LRI were not modeled using the same data and so are not 
independent in this analysis.  
The incidence of LRI hospitalisations was also modelled using DisMod. For this model, only inpatient 
utilisation data were used which were primarily from high-income countries such as the United States and 
in Western Europe, but data from Brazil, India, Indonesia, Kenya, Mexico, Nepal, the Philippines, Qatar, 205 
and Vietnam were also used (Appendix Table 3, Appendix page 31). Covariates such as the total 
inpatient visits per person and the healthcare access and quality index21 were used to help account for 
variation in healthcare availability and access. The duration in days of hospitalisation for viral LRI 
episodes was determined by a meta-analysis of studies that reported this duration.6  
Commented [CT1]: Current link, will need to be updated 
following November 5 public release of GBD 2017. 
http://ghdx.healthdata.org/gbd-2016/data-input-
sources?components=4&causes=322  
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All modelled estimates for the GBD study, including influenza attributable fractions, influenza LRI 210 
incidence, hospitalisations, and deaths, were estimated for every country and some subnational locations, 
by sex, for each age group, from 1990 to 2017. The results presented below are the mean values from a 
distribution of one thousand estimated observations (draws) for each modelled value or input parameter. 
Uncertainty intervals (UI) are reported as the 2.5th and 97.5th percentiles of the posterior distributions.  
Role of the Funding Source 215 
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results  
We estimated the quantifiable burden of disease due to influenza LRI including deaths, hospitalisations, 220 
and moderate and severe episodes (Figure 1). We estimated that 5·6% of LRI deaths (95% Uncertainty 
interval [UI] 4·3-7·1%) were attributable to influenza in 2017, accounting for 144,505 (95% UI 98,922-
202,205) deaths among all ages (Table 1) This corresponded to 0.26% of all deaths in 2017 (95% UI 0.2-
0.32%). The attributable fraction was greater among adults over 70 years old (6·3%, 95% UI 4.8-7.8%) 
compared to children under 5 (2·9%, 95% UI 2·0-4·0%) (Figure 2). The fraction of LRI deaths that were 225 
attributable to influenza ranged from 23.7% in Ukraine (95% UI 19.1-27.6%) to 1.9% in Mozambique 
(95% UI 1.6-2.2%; Appendix Figure 6C, Appendix page 35). Most influenza LRI deaths occurred 
among the elderly (70,912 deaths among adults over 70, 95% UI 50,221-94,825) (Figure 2). Among all 
ages, the highest estimated influenza LRI mortality rate occurred in the Caribbean (5.5 per 100,000, 95% 
UI 3.6-7.7) and Eastern Europe (5·2 per 100,000, 95% UI 3.5-7.2) regions while the highest mortality rate 230 
overall occurred in Taiwan (12·1 per 100,000, 95% UI 7.8-17.6) (Table 1, Figure 3). The estimated 
influenza LRI mortality rate was lowest in the Australasia region (0·9 per 100,000, 95% UI 0.5-1·27) and 
the country with the lowest influenza LRI mortality rate was Qatar (0·3 per 100,000, 95% UI 0·1-0·4) 
(Table 1, Figure 3). Nearly a third of all influenza LRI deaths occurred in India (25,517 deaths, 95% UI 
16,211-37,037), China (10,772, 95% UI 7,245-15,000), and Russia (7,979, 95% UI 5,422-11,083) (Table 235 
1). Between 1990 and 2017, the influenza LRI mortality rate decreased by 29.5% among all ages (from 
2·68 to 1·89 per 100,000). The rate of decline in this period was fastest among children under 5 (67.8%) 
and slowest among adults over 70 years (10.2%).  
Influenza was more frequently associated with non-fatal and non-severe LRI episodes. In fact, we 
estimated that influenza was present in hospitalised LRI episodes 23% less frequently than in non-240 
hospitalised LRI episodes (95% UI 9-33%). This is also reflected in the proportionally greater attribution 
of influenza to non-fatal LRI (Figure 2). Among all ages, an estimated 8·5% of LRI hospitalisations were 
attributable to influenza (95% UI 5.4-13.5%) (Figure 2). Influenza was responsible for 9,458,902LRI 
hospitalisations (95% UI 3,708,873-22,934,779), a rate of 123.8 per 100,000 (95% UI 48.5-300.2) (Table 
1, Figure 2) in 2017 and corresponding with an estimated 81,535,737 hospital-days (95% UI 24,330,208-245 
259,851,048) due to influenza LRI. The greatest number of influenza LRI episodes and hospitalisations 
occurred among childhood age groups under 10 years old (Figure 2). We estimated that there were 
2,223,923 LRI hospitalisations due to influenza (95% UI 737,701-5,979,075) among children younger 
than 5 years in 2017. However, the incidence of non-hospitalised and hospitalised influenza LRI followed 
a U-shaped curve, increasing in children and elderly adults (Figure 2). The incidence of hospitalisation 250 
due to influenza LRI was greatest in Eastern Europe (488.7 hospitalisations per 100,000, 95% UI 185.9-
1204.6) and Central Asia (303.1, 95% UI 120.5-721.6) (Table 1, Figure 4). The countries with the 
highest estimated influenza LRI hospitalisation rates were Lithuania (560.7 per 100,000, 95% UI 227.2-
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1351.7) and Russia (494.4 per 100,000, 95% UI 183.6-1241.6) while the lowest were in Nepal (9.4 per 
100,000, 95% UI 3.2-25.7) and Bangladesh (11.9 per 100,000, 95% UI 3.7-33.8) (Figure 3). Globally, 255 
17.4% (95% UI 9.6-31.0) of influenza LRI cases were hospitalised among all ages in 2017 (Appendix 
Figure 6B, Appendix page 34); the proportion hospitalised was highest in adults over 70 (45.8%, 95% 
UI 27.5-72.1) (Appendix Figure 8, Appendix page 36). The Maldives (1·3%, 95% UI 0·6-2·6) and 
Indonesia (1·2%, 95% UI 0·6-2.3) had the lowest estimated proportions of influenza LRI episodes that 
were hospitalised while Brunei (59.1%, 95% UI 29.6-100.0) and Singapore (59.0%, 95% UI 31.8-100.0) 260 
had the highest proportions (Appendix Figure 7, Appendix page 35). Although the number of influenza 
LRI hospitalisations increased between 1990 and 2017 (14.0% increase, from 8,300,111 to 9,458,902), 
the hospitalisation rate declined over this time (19.6% decrease, from 153.9 to 123.8 per 100,000).  
Among all ages, we estimated that 11.5% of LRI episodes were attributable to influenza (95% UI 10.0-
12.9%) (Figure 2). This attributable fraction was highest among middle age adult age groups and was 265 
responsible for 9·2% (95% UI 8·0-10·2%) of LRI episodes among children under 5 and 10·8% (95% UI 
9·3-12.0%) of LRI episodes among adults over 70 (Figure 2). We estimated that influenza was 
responsible for 54,480,725 LRI episodes among all ages in 2017 (95% UI 38,465,002-73,864,037; Table 
1), including 8,172,109 severe LRI episodes (5,000,450-13,295,527). Influenza episodes were most 
common in Eastern Europe (2,399.3 episodes per 100,000, 95% UI 1,717.2-3,205.6) and Southeast Asia 270 
(1,591.2 per 100,000, 95% UI 1,118.1-2160.2) (Table 1, Figure 5). The highest overall incidence 
occurred in Vietnam (3710.5 per 100,000, 95% UI 2,537.3-5,141.6) and in Lithuania (2,489.6 per 
100,000, 95% UI 1,728.2-3,469.3) while the lowest incidence occurred in Italy (63.7 per 100,000, 95% UI 
44.5-85.1) and in Israel (83.2 per 100,000, 95% UI 57.3-117.2). The incidence of influenza LRI decreased 
between 1990 and 2017 (9.7% decrease, from 789.9 to 713.1 per 100,000), but increased in young adults 275 
15-49 years (12.1% increase, from 566.1 to 634.6 per 100,000).  
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Discussion 
Summary. This manuscript provides the most thorough and comprehensive analysis of the burden of 
lower respiratory infections attributable to influenza to date, covering incidence, severe incidence, 
hospitalisations, and mortality for each age group, annually from 1990 to 2017, and geography. We 
estimated that influenza LRI caused 144,505 deaths (95% UI 98,922-200,205), 54,480,725 LRI episodes 285 
(95% UI 38,465,002-73,864,037), 8,172,109 severe LRI episodes (5,000,450-13,295,527), and 9,458,902 
LRI hospitalisations (95% UI 3,708,873-22,934,779). 
Influenza pyramid. A full picture of lower and upper respiratory tract infections (including the non-
respiratory infections), either symptomatic or inapparent, hospitalisations, and deaths is necessary to 
quantify the entire spectrum of influenza illness (Figure 1). This study has captured many, but not all of 290 
those components. Inapparent, or asymptomatic influenza virus infection is crucial for modelling the 
transmission of influenza spread. The Global Burden of Disease study does not typically estimate 
asymptomatic infections for causes of disease. There is evidence that influenza virus infection may be a 
risk factor for cardiovascular mortality,22 renal failure, and other systemic outcomes, perhaps by 
exacerbation of underlying or comorbid diseases. These outcomes may begin with a respiratory infection 295 
and might be captured in time-series analyses of influenza burden or determined through influenza 
vaccine probe studies with severe illness endpoints to measure vaccine-preventable disease incidence.23 
Our study quantified the remaining aspects of influenza disease burden, focusing exclusively on LRIs 
attributable to influenza. We have shown that a moderate amount of LRIs are attributable to influenza. 
The attributable fraction is highest in adolescents and adults but because of the greater overall risk of 300 
LRIs in young children and elderly adults, our results suggest that the greatest number of LRI episodes, 
severe episodes, hospitalisations, and deaths occur in young children and elderly adults.  
 
Appreciating age patterns in rates and counts is important in developing appropriate responses and 
interventions. Global estimates of seasonal influenza vaccine coverage were not available for this study 305 
and could provide additional evidence of disease burden. Although our study did not account for 
influenza vaccine coverage, our results help to show where the greatest impact of a seasonal or universal 
influenza vaccine could occur. Modelling studies have indicated that vaccinating targeted populations 
could reduce seasonal influenza outbreaks,24 and may help to prevent episodes and hospitalisations in 
elderly adults.25 Our results support the potential impact on the burden of influenza LRI by reducing 310 
severe and non-severe episodes and deaths and suggest that targeting specific age groups, particularly the 
elderly, and locations such as Eastern Europe and Southeast Asia could dramatically reduce the global 
burden of influenza LRI. The counterfactual strategy used in our model allow for a quantification of the 
avertable burden through vaccination or other interventions.  
Diagnostic tools. To estimate the attributable fraction of LRI that is due to influenza, we made several 315 
important analytic decisions and assumptions. Based on our analysis of the available data that reflected 
the frequency of influenza isolation among respiratory samples from pneumonia or bronchiolitis episodes 
(definition of LRI in GBD 2017), we found that RT-PCR is significantly more sensitive in detecting acute 
influenza infection than ELISA-based methods. The mean frequency of influenza positive samples was 
about 25% greater when using RT-PCR than using non-RT-PCR diagnostics (Appendix page 4), a result 320 
that is consistent with the general body of knowledge regarding molecular diagnostic methods.26 Another 
systematic review of influenza detection among acute LRI episodes in children found that PCR 
diagnostics detected influenza more than 2 times more frequently than in immunofluorescence tests.27 
One of the reasons for this finding could be due to the anatomical site where samples are collected, which 
may affect the frequency of influenza detection. Most studies use nasopharyngeal swabs due to the 325 
relative ease of collection and non-invasiveness,28 and the data from our systematic review were nearly 
exclusively from nasopharyngeal or oropharyngeal swabs. Studies have shown varying levels of 
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specificity and sensitivity in the relationship between detection  in nasopharyngeal samples and LRIs.28,29 
The time period between infection, symptoms onset, geographic regions, and sample collection could also 
play critical roles in influenza virus detection with or without molecular diagnostics. 330 
PAF data and assumptions. These results are based on approximately 650 data points from 100 sources 
in 40 countries (Appendix Figure 2; Appendix Table 2, Appendix pages 5-26). The predictive 
modelling tools used in the GBD study use space-time information and covariates to help make estimates 
for every geography, year, age. In areas with sparse data, the uncertainty around the estimates is greater. 
The modelled frequency of influenza attributable LRI episodes is a component of the counterfactual 335 
attribution strategy used in GBD 2017. The second component of the PAF model, the odds ratio, reflects 
how likely a sample that tests positive for influenza identifies the etiology of LRI. The source that we 
used to quantify this relationship is a systematic review among children under 5. Because of a lack of data 
on this relationship in older age groups, we assume that it is constant across ages, an assumption that may 
not hold because of a variety of immunological or biological differences between young children and 340 
adults. If adults are more likely than children under 5 to have an LRI episode given influenza detection, 
our estimates in adults may be an underestimate and inversely may be an over-estimate if adults are less 
likely to have an LRI episode given influenza detection than children under 5. Results from a study in 
South Africa found that the odds of severe acute respiratory illness given influenza was lower among 5-65 
years than under-5 and over-65,30 suggesting that, despite being a single study with a different case 345 
definition than used in this study, our results may be overestimates of influenza attribution in these age 
groups.  
There is evidence of a potentially important role in influenza co-infection with Streptococcus 
pneumoniae, Staphylococcus aureus, Haemophilus influenzae type B, and other bacterial pneumonias.31–33 
The interpretation of the counterfactual attribution used in the GBD, while estimated independently for 350 
each pathogen, allows for overlap in the attribution of LRI episodes or deaths due to multiple pathogens. 
However, our estimation does not explicitly account for influenza infection as a risk factor for subsequent 
bacterial infections, a potentially important burden.  
Comparisons. The GBD 2017 estimates of LRI deaths attributable to influenza are about two times 
greater than the estimates from GBD 2016. This change is largely due to an important adjustment scalar 355 
in determining how frequently viral causes of LRI are associated with mortality compared to bacterial 
causes of LRI. Our analysis found that bacterial aetiologies are more likely to lead to death than viral 
aetiologies.6 For previous GBD studies, this relationship was quantified using data from a small subset of 
countries. We reproduced this analysis for GBD 2017 using a much larger dataset of hospitalisation 
records that were coded specifically to viral or bacterial causes of LRI and where the outcome, discharge 360 
or death, was known. The ICD codes used in this step are unlikely to capture any interaction between 
influenza and bacterial aetiologies of LRI and the risk of death in viral-bacterial coinfections is probably 
higher than in viral infections alone.34 This reanalysis substantially reduced the uncertainty around this 
adjustment while also decreasing the magnitude of the scalar used to adjust the fatal influenza attributable 
fraction. A detailed description of these changes can be found in the Appendix (p 29-32, 37-39).  365 
The number of LRI deaths attributable to influenza remain much lower than a recently published report 
from Iuliano et al. 2018 that found an estimated 290,000-650,000 seasonal influenza-associated 
respiratory deaths.5 Differences in the modelling strategy account for a large amount of the variation in 
the estimates and have been explored as part of a modeling workshop between these research groups. 
Where the approach by Iuliano et al. was designed to estimate any deaths that may be considered 370 
associated with influenza, the GBD 2017 approach estimates the proportion of LRI deaths that are 
attributable to (caused by) influenza in our counter-factual framework. The GBD 2017 estimation 
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strategy starts with an overall number of LRI deaths and counterfactually attributes a fraction of these 
deaths to influenza. In contrast, Iuliano et al. use a time-series analysis to determine excess mortality 
among all respiratory-coded deaths (ICD 10 codes J00-J99) during the influenza season and uses these 375 
estimates to model annual influenza-associated respiratory deaths. While the strategy used by Iuliano 
allows for variation in burden by year and season, the approach used in GBD 2017 is robust to influenza 
occurrence, association with LRI episodes, and consistency between other causes of death, and estimates 
that were produced for every year, age, sex, and geography. The estimates produced by Iuliano and GBD 
2017 follow fundamentally different premises. Our approach has the major advantage of quantifying the 380 
potentially avertable influenza burden and our results can be used to estimate the vaccine preventable 
burden and the burden preventable by other interventions.  
A study by Lafond and colleagues27 estimated the global pediatric influenza-associated hospitalisations. 
Using a similar approach to ours, starting with a systematic review of the proportion of hospitalised 
respiratory infections among children younger than 18 and finding the product of that proportion and the 385 
number of acute LRI episodes hospitalized in 2010, they estimated 870,000 (610,000-1,237,000) 
influenza-associated hospitalisations among children younger than 5.27 This value is lower than ours 
(2,223,923, 95% UI 737,701-5,979,075 in 2017) but our estimates of the fraction of hospitalized LRI due 
to influenza are nearly identical (7.4% in Lafond et al,27 6.9% in our study) and suggests that the main 
difference is in the overall estimates of LRI hospitalisations among children younger than 5. Indeed, our 390 
estimate of 32,211,143 (95% UI 18,072,832-52,111,555) is much larger than the value used in the Lafond 
study (11,751,000).27,35 This is an example of the impact of multiple estimated values in both studies and 
that the rates of hospitalisations depends on not only on the attributable fraction of LRI due to influenza 
but also on the overall availability and usage of healthcare.  
Limitations. Our study has a number of limitations. The availability and quality of data are very 395 
important in any predictive regression model. In particular, there are a scarcity of data in several 
geographic regions such as South Asia and sub-Saharan Africa for several of our models in this analysis, 
particularly the models for LRI mortality and hospitalisation. In contrast, there is good data coverage for 
LRI incidence globally because of population representative surveys. The data that inform the attributable 
fraction of influenza are also sparse in some parts of the world, such as Central Europe and Central Asia. 400 
Strengthening the capacity for detecting influenza has been a priority among global health organisations 
largely to improve early detection systems but expanding routine surveillance may also help improve 
global burden estimates.36 Our systematic review identified a number of sources from central-latitude 
locations which identified substantial proportion of influenza in LRI episodes.37 This suggests that 
influenza may be an important cause of LRIs in tropical climates,38 an area of some current debate that 405 
argues if environmental suitability is necessary for seasonal influenza burden.  
As mentioned, due to a lack of available data we assume that the presence of influenza in a respiratory 
sample has the same risk of contributing to an LRI episode among children under 5 as for older children 
and adults. There are a number of reasons that this may not be a consistent assumption including 
immunology, biology, and circulating influenza strains. Changes in circulating influenza virus strains 410 
over time and space has been studied extensively in order to predict strains for seasonal vaccine 
development and for assessing the risk of a pandemic.39 Our study attempted to combine all strains of 
influenza into a single burden estimate and it is possible that stratification by sub-type, including 
influenza A, B, and pandemic H1N1 (H1N1pdm09), might reveal additional trends in influenza burden. 
However, it is well known that influenza burden has the potential to change dramatically from year to 415 
year and from season to season.40 We deliberately chose to include only studies that were conducted over 
the period of a full year in order to avoid biasing our estimates from studies conducted during the peak 
12 
 
influenza season. We also chose to exclude studies that tested for H1N1pdm09 exclusively because we 
believed this would bias our estimates but did include studies that tested for H1N1pdm09 concurrently 
with seasonal influenza. These decisions contributed to relative stability over time in our estimates of the 420 
attributable fraction of influenza. While our model likely failed to capture significant year-to-year 
variation in influenza burden, the purpose of this modelling approach was to minimise the effect of such 
variation in determining the attributable burden of influenza LRI.  
Call to action, reflection. While much of the public attention on influenza has centered around the global 
threat of a pandemic, rightly emphasizing its potential impact on an increasingly interconnected global 425 
community, our results show that ongoing seasonal influenza contributes to a substantial burden of lower 
respiratory tract infections. The best way to prevent influenza-specific LRI is through vaccination or 
through targeted prophylaxis and we have previously demonstrated that reducing exposure to air pollution 
and tobacco smoke could have major impacts on all LRI risk.6 As the highest burden of influenza-LRI is 
seen in low and middle income countries, additional data on influenza epidemiology in LMICs are needed 430 
to guide decisions on development of vaccines and appropriate vaccination strategies to prevent severe 
influenza illnesses in LMICs.41 Efforts to develop improved influenza vaccines that could avert a large 
annual burden of disease ranging from LRI episodes, hospitalisations, and mortality are needed.42,43 A full 
understanding of the burden of seasonal influenza could contribute to a better understanding of the 
epidemiology of the virus and preparedness in case of another influenza pandemic.  435 
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Table 1. Influenza LRI episodes, hospitalisations, and deaths from influenza LRI among all ages in 2017 by GBD country, region, and 
super-region.  
Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
Hospitalisations 
per 100,000 (95% 
UI) Episodes (95% UI) 
Incidence per 
100,000 (95% 
UI) 
Global 
144,505 
(98,922-200,205) 
1.9 
(1.3-2.6) 
9,458,902 
(3,708,873-
22,934,779) 
123.8 
(48.5-300.2) 
54,480,725 
(38,465,002-73,864,037) 
713.1 
(503.4-966.7) 
Southeast Asia, East Asia, and 
Oceania 
26,846 
(18,499-37,226) 
1.2 
(0.9-1.7) 
2,330,052 
(919,244-
5,591,636) 
107.9 
(42.6-259.0) 
13,255,832 
(9,342,350-17,963,170) 
614.0 
(432.8-832.1) 
East Asia 
14,465 
(9,848-20,453) 
1.0 
(0.7-1.4) 
883,669 
(336,420-
2,168,000) 
59.5 
(22.6-145.9) 
2,571,276 
(1,786,685-3,510,115) 
173.1 
(120.3-236.3) 
China 
10,772 
(7,245-15,500) 
0.8 
(0.5-1.1) 
739,467 
(279,032-
1,825,566) 
52.4 
(19.8-129.2) 
2,144,719 
(1,481,039-2,940,786) 
151.8 
(104.9-208.2) 
North Korea 
602 
(311-1,046) 
2.3 
(1.2-4.1) 
50,461 
(16,367-140,181) 
196.2 
(63.6-545.1) 
156,175 
(106,251-217,302) 
607.3 
(413.2-845.0) 
Taiwan 
2,858 
(1,835-4,157) 
12.1 
(7.8-17.6) 
79,906 
(28,218-206,210) 
338.8 
(119.7-874.4) 
230,314 
(160,695-310,342) 
976.6 
(681.4-1,315.9) 
Southeast Asia 
11,890 
(7,960-16,598) 
1.8 
(1.2-2.5) 
204,588 
(76,581-517,869) 
31.0 
(11.6-78.4) 
10,509,349 
(7,384,864-14,267,957) 
1,591.2 
(1,118.1-
2,160.2) 
Cambodia 
221 
(120-370) 
1.4 
(0.7-2.3) 
2,377 
(747-6,882) 
14.7 
(4.6-42.7) 
132,014 
(87,892-188,081) 
818.8 
(545.2-1,166.6) 
Indonesia 
2,994 
(1,920-4,373) 
1.2 
(0.7-1.7) 
40,440 
(14,378-107,946) 
15.7 
(5.6-41.8) 
3,316,987 
(2,261,372-4,618,922) 
1,285.0 
(876.0-1,789.3) 
Laos 
292 
(143-518) 
4.2 
(2.1-7.4) 
2,642 
(828-7,514) 
37.9 
(11.9-107.8) 
152,649 
(104,873-210,256) 
2,190.0 
(1,504.6-
3,016.5) 
Malaysia 
795 
(404-1,255) 
2.6 
(1.3-4.1) 
6,192 
(2,023-17,425) 
20.2 
(6.6-56.9) 
342,172 
(230,466-480,177) 
1,116.8 
(752.2-1,567.2) 
Maldives 
1 
(1-2) 
0.3 
(0.2-0.5) 
84 
(26-244) 
18.4 
(5.7-53.2) 
6,706 
(4,627-9,257) 
1,462.2 
(1,008.8-
2,018.4) 
Mauritius 
16 
(10-24) 
1.3 
(0.8-1.9) 
267 
(91-714) 
21.0 
(7.2-56.1) 
14,291 
(9,874-19,691) 
1,123.4 
(776.2-1,547.9) 
Myanmar 
1,091 
(600-1,826) 
2.1 
(1.1-3.5) 
10,992 
(3,615-30,390) 
20.8 
(6.8-57.6) 
609,181 
(418,457-844,597) 
1,153.9 
(792.6-1,599.8) 
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Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
Hospitalisations 
per 100,000 (95% 
UI) Episodes (95% UI) 
Incidence per 
100,000 (95% 
UI) 
Philippines 
2,037 
(1,246-3,121) 
2.0 
(1.2-3.0) 
21,624 
(7,560-57,858) 
20.9 
(7.3-55.9) 
1,168,776 
(798,033-1,615,665) 
1,129.6 
(771.3-1,561.5) 
Sri Lanka 
268 
(141-465) 
1.2 
(0.7-2.2) 
5,521 
(1,829-15,243) 
25.6 
(8.5-70.6) 
297,364 
(204,983-411,292) 
1,376.9 
(949.2-1,904.4) 
Seychelles 
4 
(2-6) 
3.7 
(2.2-5.7) 
32 
(11-87) 
32.2 
(11.0-86.6) 
1,606 
(1,110-2,212) 
1,591.2 
(1,099.7-
2,191.8) 
Thailand 
2,096 
(1,051-3,284) 
3.0 
(1.5-4.7) 
20,091 
(7,112-52,926) 
28.4 
(10.1-74.9) 
869,446 
(608,384-1,188,505) 
1,231.1 
(861.4-1,682.8) 
Timor-Leste 
22 
(9-38) 
1.7 
(0.7-3.0) 
353 
(109-1,023) 
27.4 
(8.5-79.4) 
18,923 
(12,868-26,528) 
1,469.8 
(999.5-2,060.4) 
Vietnam 
2,038 
(1,114-3,464) 
2.1 
(1.2-3.6) 
134,531 
(47,748-356,052) 
139.9 
(49.7-370.3) 
3,567,264 
(2,439,338-4,943,211) 
3,710.5 
(2,537.3-
5,141.6) 
Oceania 
491 
(272-830) 
3.9 
(2.2-6.6) 
19,193 
(6,295-54,351) 
152.3 
(49.9-431.3) 
192,464 
(134,370-264,357) 
1,527.2 
(1,066.2-
2,097.6) 
American Samoa 
1 
(1-2) 
1.7 
(1.0-2.9) 
60 
(19-171) 
107.5 
(34.8-307.9) 
618 
(424-860) 
1,110.5 
(762.2-1,545.2) 
Federated States of Micronesia 
2 
(1-4) 
2.2 
(1.0-3.9) 
121 
(39-346) 
116.7 
(37.6-333.0) 
1,255 
(863-1,743) 
1,207.7 
(830.6-1,676.9) 
Fiji 
21 
(11-35) 
2.3 
(1.3-3.8) 
1,033 
(338-2,900) 
113.9 
(37.3-319.8) 
10,167 
(7,010-14,094) 
1,121.0 
(773.0-1,554.0) 
Guam 
3 
(2-5) 
2.0 
(1.2-3.3) 
179 
(60-498) 
106.8 
(35.7-297.0) 
1,752 
(1,210-2,422) 
1,043.7 
(721.0-1,443.4) 
Kiribati 
2 
(1-4) 
1.8 
(0.9-3.2) 
121 
(37-374) 
102.4 
(31.0-316.5) 
1,170 
(776-1,695) 
989.9 
(656.3-1,433.4) 
Marshall Islands 
1 
(1-3) 
2.6 
(1.3-4.6) 
66 
(21-189) 
118.0 
(38.1-335.7) 
703 
(484-976) 
1,249.0 
(860.2-1,733.6) 
Northern Mariana Islands 
1 
(0-1) 
1.7 
(1.0-2.8) 
45 
(15-125) 
101.1 
(34.4-278.1) 
448 
(310-618) 
998.2 
(690.9-1,376.9) 
Papua New Guinea 
394 
(201-697) 
4.3 
(2.2-7.6) 
15,016 
(4,749-43,851) 
162.7 
(51.5-475.2) 
150,922 
(103,374-210,300) 
1,635.6 
(1,120.3-
2,279.0) 
Samoa 
3 
(2-6) 
1.7 
(0.9-3.0) 
239 
(75-696) 
120.1 
(37.9-350.0) 
2,279 
(1,560-3,177) 
1,145.5 
(784.3-1,597.3) 
Solomon Islands 
25 
(14-42) 
3.9 
(2.1-6.6) 
841 
(257-2,555) 
132.0 
(40.3-400.8) 
8,350 
(5,544-12,081) 
1,309.6 
(869.6-1,894.7) 
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Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
Hospitalisations 
per 100,000 (95% 
UI) Episodes (95% UI) 
Incidence per 
100,000 (95% 
UI) 
Tonga 
2 
(1-3) 
1.7 
(0.9-2.9) 
97 
(30-293) 
94.2 
(29.5-285.1) 
948 
(629-1,369) 
921.7 
(612.1-1,331.6) 
Vanuatu 
8 
(4-14) 
2.6 
(1.3-4.9) 
352 
(110-1,025) 
122.6 
(38.2-356.5) 
3,297 
(2,256-4,602) 
1,146.5 
(784.5-1,600.2) 
Central Europe, Eastern Europe, 
and Central Asia 
16,423 
(11,299-22,546) 
3.9 
(2.7-5.4) 
1,609,003 
(659,834-
3,730,806) 
386.8 
(158.6-897.0) 
6,624,018 
(4,795,541-8,752,473) 
1,592.6 
(1,153.0-
2,104.3) 
Central Asia 
2,779 
(1,847-3,961) 
3.1 
(2.0-4.4) 
275,567 
(109,605-656,085) 
303.1 
(120.5-721.6) 
1,175,062 
(866,816-1,530,700) 
1,292.3 
(953.3-1,683.5) 
Armenia 
80 
(51-118) 
2.6 
(1.7-3.9) 
11,051 
(4,073-27,308) 
365.0 
(134.5-902.1) 
40,298 
(28,311-54,453) 
1,331.2 
(935.2-1,798.8) 
Azerbaijan 
245 
(130-416) 
2.4 
(1.3-4.1) 
25,862 
(8,999-70,393) 
252.9 
(88.0-688.4) 
109,026 
(75,003-153,985) 
1,066.3 
(733.5-1,506.0) 
Georgia 
133 
(82-201) 
3.6 
(2.2-5.4) 
10,785 
(4,446-24,827) 
292.2 
(120.5-672.6) 
46,625 
(32,832-62,891) 
1,263.1 
(889.4-1,703.7) 
Kazakhstan 
632 
(391-959) 
3.5 
(2.2-5.4) 
61,161 
(22,213-156,157) 
341.6 
(124.1-872.2) 
242,644 
(169,914-329,837) 
1,355.2 
(949.0-1,842.2) 
Kyrgyzstan 
101 
(58-160) 
1.6 
(0.9-2.5) 
25,372 
(9,231-65,363) 
398.4 
(144.9-1,026.3) 
87,714 
(60,568-120,523) 
1,377.3 
(951.0-1,892.5) 
Mongolia 
66 
(35-113) 
2.0 
(1.1-3.5) 
7,881 
(2,750-20,650) 
242.4 
(84.6-635.1) 
34,725 
(24,268-46,945) 
1,068.0 
(746.4-1,443.8) 
Tajikistan 
380 
(201-650) 
4.1 
(2.2-7.0) 
24,533 
(8,204-69,208) 
265.4 
(88.7-748.7) 
111,940 
(75,705-160,521) 
1,211.0 
(819.0-1,736.5) 
Turkmenistan 
104 
(57-175) 
2.1 
(1.2-3.5) 
10,370 
(3,555-28,562) 
208.4 
(71.4-573.9) 
46,887 
(31,933-66,875) 
942.1 
(641.6-1,343.7) 
Uzbekistan 
1,039 
(604-1,635) 
3.2 
(1.9-5.1) 
98,978 
(34,506-262,244) 
307.0 
(107.0-813.5) 
455,541 
(314,931-625,682) 
1,413.1 
(976.9-1,940.9) 
Central Europe 
2,773 
(1,902-3,824) 
2.4 
(1.7-3.3) 
139,412 
(59,860-312,317) 
121.4 
(52.1-272.0) 
410,948 
(289,084-560,444) 
358.0 
(251.8-488.2) 
Albania 
32 
(17-56) 
1.2 
(0.6-2.0) 
3,209 
(1,103-8,550) 
116.0 
(39.9-309.1) 
10,108 
(6,967-13,926) 
365.4 
(251.8-503.4) 
Bosnia and Herzegovina 
33 
(19-56) 
1.0 
(0.6-1.7) 
3,612 
(1,260-9,478) 
106.3 
(37.1-278.8) 
11,494 
(7,957-15,764) 
338.1 
(234.1-463.7) 
Bulgaria 
149 
(93-225) 
2.1 
(1.3-3.2) 
8,202 
(2,969-20,708) 
116.3 
(42.1-293.6) 
23,660 
(16,533-32,203) 
335.5 
(234.4-456.6) 
Croatia 
59 
(38-88) 
1.4 
(0.9-2.1) 
4,106 
(1,802-9,138) 
96.0 
(42.1-213.7) 
10,742 
(7,484-14,957) 
251.3 
(175.1-349.8) 
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Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
Hospitalisations 
per 100,000 (95% 
UI) Episodes (95% UI) 
Incidence per 
100,000 (95% 
UI) 
Czech Republic 
303 
(195-444) 
2.9 
(1.8-4.2) 
10,901 
(4,541-24,963) 
102.9 
(42.9-235.7) 
32,151 
(22,494-43,698) 
303.5 
(212.4-412.5) 
Hungary 
95 
(61-140) 
1.0 
(0.6-1.4) 
9,314 
(3,262-24,639) 
95.7 
(33.5-253.3) 
30,434 
(20,975-41,863) 
312.9 
(215.6-430.4) 
Macedonia 
15 
(8-26) 
0.7 
(0.4-1.2) 
2,438 
(825-6,794) 
112.1 
(37.9-312.4) 
8,304 
(5,645-11,874) 
381.8 
(259.6-546.0) 
Montenegro 
7 
(4-12) 
1.2 
(0.6-1.9) 
789 
(267-2,182) 
126.1 
(42.7-348.3) 
2,562 
(1,735-3,672) 
409.0 
(277.0-586.3) 
Poland 
532 
(338-781) 
1.4 
(0.9-2.0) 
21,385 
(8,755-49,068) 
55.7 
(22.8-127.8) 
56,508 
(39,028-77,050) 
147.2 
(101.7-200.7) 
Romania 
1,191 
(769-1,732) 
6.1 
(4.0-8.9) 
65,108 
(27,568-147,024) 
335.0 
(141.9-756.5) 
173,656 
(121,356-235,007) 
893.6 
(624.5-1,209.3) 
Serbia 
142 
(83-222) 
1.6 
(0.9-2.5) 
5,841 
(2,252-14,325) 
65.8 
(25.4-161.4) 
24,288 
(16,809-33,320) 
273.7 
(189.4-375.5) 
Slovakia 
159 
(95-246) 
2.9 
(1.8-4.5) 
5,485 
(2,165-13,237) 
101.2 
(40.0-244.3) 
17,362 
(12,062-23,734) 
320.4 
(222.6-438.0) 
Slovenia 
55 
(34-81) 
2.6 
(1.7-3.9) 
2,548 
(1,019-5,857) 
123.2 
(49.2-283.1) 
6,162 
(4,285-8,402) 
297.9 
(207.1-406.1) 
Eastern Europe 
10,871 
(7,420-15,091) 
5.2 
(3.5-7.2) 
1,027,209 
(390,825-
2,532,133) 
488.7 
(185.9-1,204.6) 
5,043,230 
(3,609,558-6,738,064) 
2,399.3 
(1,717.2-
3,205.6) 
Belarus 
245 
(147-385) 
2.6 
(1.5-4.1) 
45,704 
(15,287-127,316) 
481.5 
(161.1-1,341.4) 
231,642 
(158,083-328,479) 
2,440.6 
(1,665.6-
3,460.9) 
Estonia 
43 
(26-67) 
3.3 
(2.0-5.1) 
6,134 
(2,195-15,841) 
466.6 
(166.9-1,205.1) 
28,280 
(19,885-38,252) 
2,151.3 
(1,512.7-
2,909.9) 
Latvia 
78 
(47-119) 
4.0 
(2.4-6.1) 
8,272 
(3,265-19,880) 
425.2 
(167.8-1,021.9) 
43,527 
(30,659-58,788) 
2,237.4 
(1,576.0-
3,021.9) 
Lithuania 
141 
(88-211) 
4.9 
(3.1-7.4) 
15,966 
(6,469-38,491) 
560.7 
(227.2-1,351.7) 
70,896 
(49,212-98,794) 
2,489.6 
(1,728.2-
3,469.3) 
Moldova 
198 
(127-294) 
5.3 
(3.4-7.9) 
16,813 
(5,999-44,364) 
451.7 
(161.2-1,192.0) 
89,159 
(62,815-120,612) 
2,395.6 
(1,687.7-
3,240.7) 
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Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
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100,000 (95% 
UI) 
Russian Federation 
7,979 
(5,422-11,083) 
5.5 
(3.7-7.6) 
722,750 
(268,439-
1,815,081) 
494.4 
(183.6-1,241.6) 
3,504,184 
(2,454,367-4,756,911) 
2,397.0 
(1,678.9-
3,253.9) 
Ukraine 
2,186 
(1,368-3,272) 
4.9 
(3.1-7.3) 
211,171 
(75,486-549,558) 
472.5 
(168.9-1,229.7) 
1,075,834 
(755,918-1,455,967) 
2,407.4 
(1,691.5-
3,258.0) 
High-income 
23,542 
(16,580-31,589) 
2.2 
(1.5-2.9) 
821,039 
(366,083-
1,725,106) 
76.4 
(34.1-160.5) 
2,269,080 
(1,667,513-2,962,557) 
211.1 
(155.1-275.6) 
High-income Asia Pacific 
7,546 
(5,129-10,388) 
4.0 
(2.7-5.6) 
157,103 
(64,431-357,083) 
84.0 
(34.4-190.9) 
273,087 
(192,215-369,645) 
146.0 
(102.8-197.6) 
Brunei 
6 
(3-9) 
1.3 
(0.8-2.1) 
444 
(151-1,134) 
102.6 
(35.0-262.2) 
751 
(512-1,045) 
173.7 
(118.3-241.6) 
Japan 
6,543 
(4,438-9,039) 
5.1 
(3.5-7.0) 
103,804 
(43,013-236,360) 
80.9 
(33.5-184.1) 
181,588 
(126,697-247,752) 
141.5 
(98.7-193.0) 
South Korea 
830 
(535-1,208) 
1.6 
(1.0-2.3) 
43,774 
(15,744-108,486) 
83.1 
(29.9-206.0) 
74,586 
(52,291-101,379) 
141.6 
(99.3-192.5) 
Singapore 
167 
(111-237) 
3.0 
(2.0-4.3) 
9,521 
(3,629-22,095) 
171.0 
(65.2-396.8) 
16,148 
(11,406-21,742) 
290.0 
(204.8-390.4) 
Australasia 
243 
(152-361) 
0.9 
(0.5-1.3) 
11,315 
(4,276-27,229) 
39.9 
(15.1-95.9) 
38,585 
(26,752-52,710) 
135.9 
(94.2-185.7) 
Australia 
208 
(127-314) 
0.9 
(0.5-1.3) 
9,166 
(3,353-22,541) 
38.3 
(14.0-94.1) 
29,982 
(20,725-41,117) 
125.2 
(86.6-171.7) 
New Zealand 
35 
(21-52) 
0.8 
(0.5-1.2) 
2,098 
(835-4,981) 
47.2 
(18.8-112.0) 
8,591 
(5,880-11,884) 
193.1 
(132.2-267.2) 
Western Europe 
9,208 
(6,564-12,296) 
2.1 
(1.5-2.8) 
259,545 
(119,111-528,501) 
59.9 
(27.5-122.1) 
595,260 
(453,391-754,998) 
137.5 
(104.7-174.4) 
Andorra 
2 
(1-3) 
2.4 
(1.3-4.0) 
42 
(16-104) 
52.5 
(19.6-129.7) 
106 
(75-144) 
132.4 
(94.3-180.6) 
Austria 
63 
(41-93) 
0.7 
(0.5-1.1) 
4,960 
(2,062-10,882) 
56.4 
(23.4-123.8) 
10,984 
(7,760-14,875) 
124.9 
(88.2-169.2) 
Belgium 
367 
(231-543) 
3.2 
(2.0-4.8) 
9,803 
(4,157-21,579) 
86.6 
(36.7-190.6) 
19,427 
(13,631-26,588) 
171.6 
(120.4-234.9) 
Cyprus 
12 
(7-20) 
0.9 
(0.5-1.6) 
348 
(141-821) 
27.6 
(11.2-65.0) 
1,138 
(806-1,537) 
90.1 
(63.9-121.7) 
Denmark 
155 
(98-227) 
2.7 
(1.7-4.0) 
3,577 
(1,411-8,227) 
62.4 
(24.6-143.5) 
7,872 
(5,595-10,560) 
137.3 
(97.6-184.2) 
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Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
Hospitalisations 
per 100,000 (95% 
UI) Episodes (95% UI) 
Incidence per 
100,000 (95% 
UI) 
Finland 
74 
(46-110) 
1.3 
(0.8-2.0) 
5,021 
(2,019-11,292) 
91.0 
(36.6-204.6) 
10,529 
(7,413-14,306) 
190.8 
(134.3-259.3) 
France 
1,453 
(892-2,181) 
2.2 
(1.4-3.3) 
36,243 
(13,656-87,943) 
55.2 
(20.8-133.8) 
88,423 
(62,479-119,622) 
134.6 
(95.1-182.0) 
Germany 
1,376 
(862-2,068) 
1.7 
(1.0-2.5) 
48,637 
(19,705-111,643) 
58.4 
(23.7-134.0) 
101,297 
(72,025-137,386) 
121.6 
(86.5-164.9) 
Greece 
280 
(175-411) 
2.7 
(1.7-4.0) 
6,339 
(2,433-14,982) 
60.9 
(23.4-144.0) 
14,844 
(10,601-19,801) 
142.7 
(101.9-190.4) 
Iceland 
6 
(4-9) 
1.8 
(1.2-2.8) 
163 
(64-387) 
48.3 
(19.0-114.7) 
421 
(297-569) 
124.7 
(88.0-168.7) 
Ireland 
89 
(56-131) 
1.8 
(1.1-2.7) 
2,063 
(772-5,056) 
42.4 
(15.9-104.0) 
5,517 
(3,896-7,456) 
113.5 
(80.2-153.4) 
Israel 
115 
(71-175) 
1.3 
(0.8-2.0) 
2,837 
(1,047-7,241) 
31.7 
(11.7-80.9) 
7,450 
(5,126-10,486) 
83.2 
(57.3-117.2) 
Italy 
472 
(292-703) 
0.8 
(0.5-1.2) 
17,108 
(7,108-37,363) 
28.2 
(11.7-61.7) 
38,402 
(26,972-51,561) 
63.4 
(44.5-85.1) 
Luxembourg 
10 
(6-15) 
1.6 
(1.0-2.5) 
287 
(114-658) 
48.6 
(19.4-111.5) 
713 
(505-961) 
120.7 
(85.6-162.7) 
Malta 
11 
(7-17) 
2.6 
(1.7-3.9) 
256 
(103-593) 
59.0 
(23.6-136.6) 
624 
(445-837) 
143.7 
(102.4-192.8) 
Netherlands 
388 
(249-576) 
2.3 
(1.5-3.4) 
8,193 
(3,176-19,528) 
48.1 
(18.7-114.7) 
19,494 
(13,912-26,452) 
114.5 
(81.7-155.3) 
Norway 
192 
(128-270) 
3.6 
(2.4-5.1) 
9,075 
(3,809-19,935) 
172.4 
(72.4-378.8) 
25,777 
(17,981-35,171) 
489.8 
(341.6-668.2) 
Portugal 
470 
(301-685) 
4.4 
(2.8-6.4) 
4,747 
(1,871-11,184) 
44.4 
(17.5-104.7) 
16,582 
(11,860-22,083) 
155.2 
(111.0-206.7) 
Spain 
729 
(463-1,065) 
1.6 
(1.0-2.3) 
17,490 
(6,685-41,401) 
37.7 
(14.4-89.2) 
42,283 
(30,137-55,992) 
91.1 
(65.0-120.7) 
Sweden 
228 
(145-338) 
2.3 
(1.4-3.4) 
7,430 
(2,789-18,059) 
74.0 
(27.8-179.8) 
16,812 
(11,725-23,015) 
167.4 
(116.7-229.1) 
Switzerland 
208 
(128-312) 
2.4 
(1.5-3.6) 
7,575 
(3,128-17,044) 
88.2 
(36.4-198.4) 
17,756 
(12,528-24,192) 
206.6 
(145.8-281.5) 
United Kingdom 
2,499 
(1,680-3,464) 
3.7 
(2.5-5.2) 
67,089 
(30,367-138,355) 
100.7 
(45.6-207.6) 
148,172 
(105,331-198,511) 
222.4 
(158.1-297.9) 
England 
2,103 
(1,409-2,929) 
3.8 
(2.5-5.2) 
60,961 
(27,793-124,775) 
108.8 
(49.6-222.6) 
133,030 
(94,272-178,953) 
237.4 
(168.2-319.3) 
Northern Ireland 
65 
(40-97) 
3.4 
(2.1-5.1) 
1,092 
(418-2,624) 
57.0 
(21.8-137.1) 
2,679 
(1,901-3,599) 
139.9 
(99.3-188.0) 
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Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
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per 100,000 (95% 
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Scotland 
187 
(116-280) 
3.4 
(2.1-5.1) 
3,083 
(1,186-7,323) 
56.0 
(21.6-133.1) 
7,290 
(5,203-9,739) 
132.5 
(94.6-177.0) 
Wales 
144 
(91-214) 
4.5 
(2.9-6.7) 
2,258 
(873-5,286) 
71.1 
(27.5-166.4) 
5,178 
(3,692-6,916) 
163.0 
(116.2-217.7) 
Southern Latin America 
2,582 
(1,759-3,631) 
3.9 
(2.7-5.5) 
78,320 
(31,961-181,785) 
119.4 
(48.7-277.1) 
340,895 
(250,568-447,727) 
519.6 
(381.9-682.4) 
Argentina 
1,932 
(1,222-2,853) 
4.4 
(2.8-6.4) 
45,876 
(16,689-116,857) 
103.6 
(37.7-264.0) 
185,768 
(127,496-257,640) 
419.7 
(288.0-582.0) 
Chile 
523 
(324-785) 
2.9 
(1.8-4.4) 
27,567 
(10,883-67,548) 
153.8 
(60.7-377.0) 
137,706 
(92,797-197,509) 
768.5 
(517.9-1,102.3) 
Uruguay 
127 
(80-190) 
3.7 
(2.3-5.6) 
4,292 
(1,587-10,528) 
125.4 
(46.4-307.7) 
16,808 
(11,701-22,980) 
491.3 
(342.0-671.6) 
High-income North America 
3,962 
(2,665-5,516) 
1.1 
(0.7-1.5) 
195,031 
(79,949-444,280) 
54.0 
(22.2-123.1) 
1,013,619 
(711,497-1,375,719) 
280.9 
(197.2-381.2) 
Canada 
285 
(174-427) 
0.8 
(0.5-1.2) 
15,898 
(5,976-38,379) 
44.2 
(16.6-106.7) 
78,005 
(54,184-106,510) 
216.8 
(150.6-296.0) 
Greenland 
1 
(0-1) 
0.9 
(0.5-1.5) 
27 
(10-68) 
48.5 
(17.6-121.5) 
156 
(108-213) 
277.6 
(192.5-378.8) 
United States 
3,676 
(2,470-5,135) 
1.1 
(0.8-1.6) 
178,522 
(73,122-407,443) 
55.0 
(22.5-125.4) 
935,170 
(655,596-1,272,353) 
287.9 
(201.8-391.7) 
Latin America and Caribbean 
13,366 
(9,166-18,419) 
2.3 
(1.6-3.2) 
434,058 
(177,361-
1,028,775) 
74.6 
(30.5-176.8) 
2,663,821 
(1,871,378-3,628,127) 
457.7 
(321.6-623.4) 
Caribbean 
2,523 
(1,688-3,583) 
5.5 
(3.6-7.7) 
74,991 
(28,488-188,074) 
162.1 
(61.6-406.5) 
480,812 
(350,216-631,423) 
1,039.3 
(757.0-1,364.8) 
Antigua and Barbuda 
6 
(3-9) 
6.3 
(3.9-9.7) 
146 
(51-388) 
163.9 
(56.8-436.1) 
955 
(660-1,298) 
1,074.1 
(742.4-1,459.3) 
The Bahamas 
13 
(8-20) 
3.4 
(2.0-5.3) 
380 
(131-1,049) 
101.1 
(34.8-279.5) 
2,515 
(1,727-3,536) 
669.9 
(460.0-941.9) 
Barbados 
32 
(20-48) 
10.8 
(6.7-16.2) 
692 
(251-1,780) 
233.8 
(84.9-601.7) 
3,940 
(2,759-5,296) 
1,331.8 
(932.4-1,789.8) 
Belize 
19 
(11-29) 
4.7 
(2.8-7.3) 
491 
(164-1,357) 
124.4 
(41.4-343.6) 
3,684 
(2,515-5,057) 
932.7 
(636.7-1,280.5) 
Bermuda 
3 
(2-4) 
4.5 
(2.7-6.8) 
103 
(37-267) 
156.7 
(56.3-405.9) 
612 
(428-824) 
929.2 
(649.9-1,250.9) 
Cuba 
699 
(444-1,029) 
6.1 
(3.9-9.0) 
15,881 
(5,816-41,605) 
139.6 
(51.1-365.7) 
84,501 
(59,549-115,471) 
742.8 
(523.4-1,015.0) 
21 
 
Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
Hospitalisations 
per 100,000 (95% 
UI) Episodes (95% UI) 
Incidence per 
100,000 (95% 
UI) 
Dominica 
5 
(3-8) 
7.8 
(4.7-11.9) 
130 
(46-343) 
188.9 
(66.2-497.4) 
792 
(550-1,072) 
1,148.9 
(797.6-1,555.4) 
Dominican Republic 
384 
(211-622) 
3.7 
(2.0-5.9) 
17,553 
(5,804-47,989) 
167.9 
(55.5-459.1) 
121,309 
(82,770-166,707) 
1,160.7 
(791.9-1,595.0) 
Grenada 
10 
(6-15) 
9.1 
(5.7-13.7) 
205 
(73-543) 
184.5 
(65.5-489.6) 
1,086 
(758-1,504) 
979.4 
(683.6-1,356.0) 
Guyana 
43 
(26-67) 
5.8 
(3.4-9.0) 
976 
(327-2,647) 
131.4 
(44.1-356.6) 
6,831 
(4,675-9,355) 
920.3 
(629.8-1,260.3) 
Haiti 
737 
(372-1,300) 
6.2 
(3.2-11.0) 
21,624 
(7,024-60,135) 
182.9 
(59.4-508.5) 
146,372 
(99,856-200,810) 
1,237.8 
(844.5-1,698.2) 
Jamaica 
88 
(50-142) 
3.2 
(1.8-5.1) 
3,557 
(1,210-9,606) 
128.0 
(43.5-345.6) 
24,844 
(17,079-33,892) 
893.9 
(614.5-1,219.5) 
Puerto Rico 
285 
(179-422) 
7.8 
(4.9-11.5) 
7,602 
(2,745-19,711) 
207.4 
(74.9-537.7) 
43,293 
(30,302-58,178) 
1,181.0 
(826.6-1,587.0) 
Saint Lucia 
10 
(6-15) 
5.7 
(3.4-8.6) 
296 
(103-786) 
167.6 
(58.4-445.6) 
1,949 
(1,349-2,644) 
1,104.3 
(764.7-1,498.1) 
Saint Vincent and the 
Grenadines 
8 
(5-12) 
6.9 
(4.2-10.5) 
202 
(71-530) 
177.0 
(62.3-464.8) 
1,269 
(880-1,719) 
1,112.0 
(771.5-1,506.6) 
Suriname 
31 
(19-48) 
5.4 
(3.2-8.3) 
746 
(256-1,978) 
130.3 
(44.8-345.5) 
4,947 
(3,417-6,729) 
864.2 
(597.0-1,175.5) 
Trinidad and Tobago 
55 
(31-90) 
4.0 
(2.2-6.5) 
1,973 
(686-5,290) 
141.8 
(49.3-380.1) 
13,336 
(9,229-18,119) 
958.2 
(663.1-1,301.8) 
Virgin Islands, U.S. 
6 
(3-9) 
5.4 
(3.2-8.5) 
175 
(63-450) 
166.6 
(59.7-428.7) 
1,045 
(731-1,409) 
995.9 
(696.1-1,342.3) 
Andean Latin America 
1,460 
(932-2,146) 
2.4 
(1.5-3.5) 
21,874 
(8,264-54,678) 
35.6 
(13.4-89.0) 
426,838 
(293,165-590,776) 
694.6 
(477.1-961.4) 
Bolivia 
268 
(140-448) 
2.3 
(1.2-3.9) 
3,537 
(1,175-9,740) 
30.6 
(10.2-84.4) 
71,806 
(49,200-99,623) 
622.1 
(426.2-863.1) 
Ecuador 
278 
(173-417) 
1.7 
(1.0-2.5) 
6,085 
(2,428-14,671) 
36.5 
(14.6-87.9) 
124,849 
(85,523-173,128) 
748.2 
(512.5-1,037.6) 
Peru 
914 
(547-1,408) 
2.8 
(1.6-4.2) 
12,232 
(4,313-32,093) 
36.8 
(13.0-96.6) 
230,183 
(158,442-318,024) 
692.9 
(477.0-957.3) 
Central Latin America 
3,315 
(2,244-4,625) 
1.3 
(0.9-1.8) 
113,267 
(40,984-295,085) 
44.3 
(16.0-115.5) 
1,133,837 
(776,479-1,573,322) 
443.8 
(303.9-615.8) 
Colombia 
594 
(364-902) 
1.2 
(0.7-1.8) 
27,854 
(8,978-79,128) 
55.0 
(17.7-156.4) 
272,841 
(182,846-385,512) 
539.1 
(361.3-761.8) 
Costa Rica 
30 
(18-46) 
0.6 
(0.4-1.0) 
1,793 
(570-5,115) 
38.5 
(12.2-109.9) 
19,199 
(12,912-27,052) 
412.6 
(277.5-581.3) 
22 
 
Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
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per 100,000 (95% 
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UI) 
El Salvador 
81 
(43-132) 
1.3 
(0.7-2.2) 
1,980 
(645-5,562) 
32.5 
(10.6-91.4) 
18,253 
(12,250-25,523) 
299.9 
(201.3-419.3) 
Guatemala 
539 
(330-814) 
3.2 
(1.9-4.8) 
12,878 
(4,182-36,330) 
76.1 
(24.7-214.7) 
115,992 
(77,048-166,390) 
685.4 
(455.3-983.1) 
Honduras 
63 
(32-115) 
0.7 
(0.3-1.2) 
6,284 
(1,896-18,785) 
66.2 
(20.0-197.8) 
61,352 
(40,931-87,911) 
645.9 
(430.9-925.5) 
Mexico 
1,662 
(1,112-2,347) 
1.3 
(0.9-1.9) 
49,282 
(18,493-126,341) 
38.9 
(14.6-99.8) 
502,888 
(342,997-703,587) 
397.3 
(271.0-555.9) 
Nicaragua 
23 
(13-37) 
0.4 
(0.2-0.6) 
1,290 
(399-3,763) 
20.2 
(6.2-58.8) 
13,401 
(8,935-18,932) 
209.5 
(139.7-296.0) 
Panama 
47 
(29-72) 
1.2 
(0.7-1.8) 
1,930 
(628-5,433) 
49.2 
(16.0-138.6) 
18,186 
(12,189-25,681) 
463.8 
(310.8-654.9) 
Venezuela 
276 
(162-434) 
0.9 
(0.5-1.4) 
10,851 
(3,531-30,655) 
35.2 
(11.5-99.4) 
110,842 
(74,516-156,273) 
359.5 
(241.7-506.9) 
Tropical Latin America 
6,069 
(4,003-8,631) 
2.8 
(1.8-3.9) 
176,848 
(72,594-414,204) 
80.8 
(33.2-189.4) 
620,005 
(420,101-871,097) 
283.4 
(192.1-398.2) 
Brazil 
5,880 
(3,875-8,392) 
2.8 
(1.8-4.0) 
163,835 
(67,495-382,496) 
77.3 
(31.9-180.6) 
569,012 
(384,199-801,950) 
268.6 
(181.4-378.6) 
Paraguay 
189 
(106-308) 
2.7 
(1.5-4.5) 
13,720 
(4,460-38,661) 
197.9 
(64.3-557.8) 
51,208 
(34,557-71,672) 
738.8 
(498.6-1,034.1) 
North Africa and Middle East 
5,503 
(3,569-8,101) 
0.9 
(0.6-1.3) 
745,571 
(252,545-
2,026,725) 
124.2 
(42.1-337.7) 
4,655,896 
(3,180,375-6,468,301) 
775.7 
(529.9-1,077.7) 
North Africa and Middle East 
5,503 
(3,569-8,101) 
0.9 
(0.6-1.3) 
745,571 
(252,545-
2,026,725) 
124.2 
(42.1-337.7) 
4,655,896 
(3,180,375-6,468,301) 
775.7 
(529.9-1,077.7) 
Afghanistan 
772 
(382-1,359) 
2.4 
(1.2-4.1) 
74,237 
(22,127-223,264) 
226.0 
(67.3-679.5) 
394,684 
(260,090-570,945) 
1,201.3 
(791.6-1,737.8) 
Algeria 
316 
(174-532) 
0.8 
(0.4-1.3) 
53,441 
(17,366-151,712) 
132.1 
(42.9-374.9) 
320,242 
(216,542-452,477) 
791.4 
(535.2-1,118.2) 
Bahrain 
7 
(4-12) 
0.5 
(0.3-0.8) 
1,487 
(472-4,330) 
101.2 
(32.1-294.5) 
10,174 
(6,930-14,305) 
692.0 
(471.3-972.9) 
Egypt 
709 
(347-1,281) 
0.7 
(0.4-1.3) 
97,542 
(29,689-280,838) 
101.1 
(30.8-291.1) 
588,112 
(394,804-818,494) 
609.5 
(409.2-848.3) 
Iran 
669 
(420-953) 
0.8 
(0.5-1.2) 
84,399 
(28,824-230,344) 
102.7 
(35.1-280.3) 
482,343 
(332,350-674,604) 
587.0 
(404.4-820.9) 
Iraq 
179 
(98-300) 
0.4 
(0.2-0.7) 
54,845 
(16,402-165,460) 
126.6 
(37.9-382.1) 
357,249 
(237,919-511,508) 
825.0 
(549.4-1,181.2) 
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Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
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Hospitalisations 
per 100,000 (95% 
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Incidence per 
100,000 (95% 
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Jordan 
59 
(33-96) 
0.6 
(0.3-0.9) 
11,777 
(4,076-32,241) 
110.6 
(38.3-302.8) 
84,268 
(56,507-119,922) 
791.4 
(530.7-1,126.2) 
Kuwait 
63 
(39-96) 
1.5 
(0.9-2.2) 
6,836 
(2,218-19,320) 
160.4 
(52.1-453.3) 
46,621 
(31,570-65,186) 
1,093.8 
(740.7-1,529.4) 
Lebanon 
53 
(29-90) 
0.6 
(0.3-1.1) 
12,416 
(3,813-37,646) 
145.9 
(44.8-442.3) 
81,802 
(54,859-116,451) 
961.0 
(644.5-1,368.1) 
Libya 
62 
(33-106) 
0.9 
(0.5-1.5) 
9,235 
(2,953-27,055) 
133.7 
(42.7-391.6) 
62,159 
(42,058-87,768) 
899.7 
(608.8-1,270.4) 
Morocco 
645 
(340-1,099) 
1.8 
(1.0-3.1) 
84,116 
(27,216-237,416) 
237.0 
(76.7-669.0) 
509,409 
(345,411-710,668) 
1,435.4 
(973.3-2,002.5) 
Palestine 
36 
(21-60) 
0.7 
(0.4-1.2) 
6,759 
(2,080-20,038) 
139.3 
(42.9-413.0) 
43,580 
(29,098-62,273) 
898.2 
(599.7-1,283.4) 
Oman 
29 
(15-50) 
0.6 
(0.3-1.1) 
4,790 
(1,529-13,948) 
105.6 
(33.7-307.5) 
35,161 
(23,963-49,409) 
775.2 
(528.3-1,089.3) 
Qatar 
7 
(4-12) 
0.2 
(0.1-0.4) 
2,821 
(899-8,206) 
102.7 
(32.7-298.7) 
18,877 
(12,923-26,425) 
687.1 
(470.4-961.9) 
Saudi Arabia 
272 
(145-462) 
0.8 
(0.4-1.3) 
35,796 
(11,567-104,381) 
103.9 
(33.6-303.0) 
266,538 
(181,404-374,349) 
773.8 
(526.7-1,086.8) 
Sudan 
444 
(209-838) 
1.1 
(0.5-2.1) 
63,504 
(18,995-191,483) 
157.8 
(47.2-475.7) 
354,424 
(235,250-509,563) 
880.4 
(584.4-1,265.8) 
Syria 
142 
(74-242) 
0.8 
(0.4-1.3) 
21,642 
(6,771-63,554) 
119.4 
(37.3-350.5) 
148,140 
(99,524-210,436) 
817.0 
(548.9-1,160.6) 
Tunisia 
120 
(63-205) 
1.0 
(0.6-1.8) 
17,808 
(5,822-50,585) 
155.6 
(50.9-442.1) 
103,327 
(70,085-145,646) 
903.0 
(612.5-1,272.9) 
Turkey 
566 
(332-876) 
0.7 
(0.4-1.1) 
44,027 
(16,679-109,899) 
54.7 
(20.7-136.6) 
342,108 
(238,860-465,526) 
425.2 
(296.9-578.6) 
United Arab Emirates 
46 
(19-89) 
0.5 
(0.2-0.9) 
7,457 
(2,445-21,575) 
76.6 
(25.1-221.6) 
57,936 
(39,971-80,778) 
595.2 
(410.6-829.8) 
Yemen 
301 
(146-554) 
1.0 
(0.5-1.8) 
61,139 
(18,499-185,628) 
200.8 
(60.8-609.6) 
346,953 
(230,410-498,728) 
1,139.5 
(756.7-1,637.9) 
South Asia 
31,382 
(20,121-45,490) 
1.8 
(1.1-2.6) 
765,451 
(255,142-
2,096,138) 
42.9 
(14.3-117.6) 
18,950,286 
(12,934,681-26,373,644) 
1,063.0 
(725.6-1,479.4) 
South Asia 
31,382 
(20,121-45,490) 
1.8 
(1.1-2.6) 
765,451 
(255,142-
2,096,138) 
42.9 
(14.3-117.6) 
18,950,286 
(12,934,681-26,373,644) 
1,063.0 
(725.6-1,479.4) 
Bangladesh 
1,000 
(534-1,741) 
0.6 
(0.3-1.1) 
18,658 
(5,753-53,093) 
11.9 
(3.7-33.8) 
718,521 
(483,918-1,005,573) 
457.7 
(308.3-640.6) 
24 
 
Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
Hospitalisations 
per 100,000 (95% 
UI) Episodes (95% UI) 
Incidence per 
100,000 (95% 
UI) 
Bhutan 
10 
(5-17) 
1.0 
(0.5-1.7) 
199 
(59-588) 
20.8 
(6.2-61.4) 
8,734 
(5,901-12,201) 
912.2 
(616.3-1,274.4) 
India 
25,517 
(16,308-37,037) 
1.8 
(1.2-2.7) 
588,160 
(196,228-
1,611,329) 
42.6 
(14.2-116.7) 
13,966,155 
(9,448,863-19,552,248) 
1,011.6 
(684.4-1,416.3) 
Nepal 
475 
(245-811) 
1.6 
(0.8-2.7) 
2,809 
(954-7,668) 
9.4 
(3.2-25.7) 
207,897 
(140,121-292,772) 
695.5 
(468.8-979.4) 
Pakistan 
4,381 
(2,164-7,838) 
2.0 
(1.0-3.7) 
126,080 
(37,625-378,217) 
58.8 
(17.6-176.5) 
4,058,959 
(2,720,607-5,746,060) 
1,894.2 
(1,269.6-
2,681.5) 
Sub-Saharan Africa 
27,443 
(17,380-40,491) 
2.7 
(1.7-3.9) 
1,597,833 
(555,739-
4,249,918) 
155.7 
(54.2-414.2) 
6,052,010 
(4,188,778-8,317,538) 
589.8 
(408.2-810.6) 
Central Sub-Saharan Africa 
4,104 
(2,330-6,712) 
3.4 
(1.9-5.5) 
293,238 
(98,081-811,775) 
241.0 
(80.6-667.2) 
936,919 
(635,980-1,310,283) 
770.0 
(522.7-1,076.9) 
Angola 
712 
(371-1,220) 
2.5 
(1.3-4.3) 
52,004 
(17,253-144,533) 
184.4 
(61.2-512.5) 
170,290 
(115,655-238,370) 
603.8 
(410.1-845.2) 
Central African Republic 
240 
(117-431) 
5.2 
(2.5-9.3) 
12,268 
(3,999-34,524) 
265.4 
(86.5-746.9) 
39,246 
(26,703-54,795) 
849.0 
(577.7-1,185.4) 
Congo 
137 
(72-235) 
2.8 
(1.5-4.8) 
9,784 
(3,264-27,031) 
199.1 
(66.4-550.2) 
32,457 
(22,224-45,145) 
660.6 
(452.3-918.9) 
Democratic Republic of the 
Congo 
2,949 
(1,513-5,141) 
3.6 
(1.9-6.4) 
213,545 
(69,086-607,635) 
264.0 
(85.4-751.2) 
674,930 
(454,675-953,762) 
834.4 
(562.1-1,179.2) 
Equatorial Guinea 
20 
(10-37) 
1.5 
(0.8-2.8) 
2,328 
(750-6,650) 
173.1 
(55.7-494.4) 
8,490 
(5,775-11,832) 
631.2 
(429.3-879.6) 
Gabon 
45 
(24-75) 
2.6 
(1.4-4.4) 
3,484 
(1,174-9,575) 
204.6 
(68.9-562.4) 
11,536 
(7,922-15,991) 
677.5 
(465.3-939.2) 
Eastern Sub-Saharan Africa 
6,629 
(4,199-9,733) 
1.7 
(1.1-2.5) 
430,037 
(145,847-
1,167,492) 
109.4 
(37.1-296.9) 
2,182,660 
(1,503,652-2,993,552) 
555.1 
(382.4-761.4) 
Burundi 
210 
(108-366) 
1.9 
(1.0-3.4) 
12,793 
(4,039-36,528) 
117.3 
(37.0-335.0) 
66,425 
(44,795-92,741) 
609.1 
(410.8-850.4) 
Comoros 
13 
(7-22) 
1.8 
(1.0-3.0) 
739 
(246-2,030) 
102.8 
(34.2-282.6) 
3,917 
(2,672-5,414) 
545.3 
(372.0-753.7) 
Djibouti 
15 
(7-27) 
1.3 
(0.7-2.4) 
996 
(325-2,800) 
89.5 
(29.2-251.6) 
5,319 
(3,621-7,369) 
477.9 
(325.3-662.1) 
Eritrea 
115 
(58-202) 
2.0 
(1.0-3.4) 
6,589 
(2,110-18,812) 
112.5 
(36.0-321.1) 
36,337 
(24,569-50,604) 
620.2 
(419.3-863.7) 
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Ethiopia 
993 
(599-1,508) 
1.0 
(0.6-1.5) 
69,381 
(22,749-191,550) 
67.4 
(22.1-186.2) 
338,784 
(230,186-467,732) 
329.3 
(223.7-454.6) 
Kenya 
853 
(537-1,291) 
1.8 
(1.1-2.7) 
73,585 
(24,190-206,358) 
152.3 
(50.1-427.0) 
365,616 
(244,861-512,372) 
756.5 
(506.7-1,060.2) 
Madagascar 
881 
(449-1,545) 
3.4 
(1.7-5.9) 
57,342 
(18,563-164,401) 
219.6 
(71.1-629.7) 
299,606 
(203,824-417,080) 
1,147.5 
(780.7-1,597.5) 
Malawi 
352 
(191-583) 
2.0 
(1.1-3.4) 
21,587 
(6,866-61,435) 
125.6 
(39.9-357.4) 
110,066 
(73,765-154,332) 
640.2 
(429.1-897.7) 
Mozambique 
266 
(138-460) 
0.9 
(0.5-1.5) 
16,015 
(5,120-46,612) 
53.3 
(17.0-155.2) 
89,219 
(60,401-125,851) 
297.0 
(201.1-419.0) 
Rwanda 
183 
(96-315) 
1.5 
(0.8-2.5) 
13,288 
(4,113-38,844) 
105.8 
(32.8-309.4) 
67,600 
(44,186-97,203) 
538.5 
(352.0-774.3) 
Somalia 
357 
(176-639) 
2.1 
(1.0-3.8) 
17,273 
(5,413-50,276) 
102.3 
(32.1-297.8) 
88,369 
(59,527-123,548) 
523.5 
(352.6-731.9) 
South Sudan 
294 
(146-523) 
3.0 
(1.5-5.3) 
12,147 
(3,763-35,188) 
122.2 
(37.9-354.0) 
59,878 
(40,191-83,929) 
602.3 
(404.3-844.3) 
Tanzania 
1,438 
(772-2,397) 
2.7 
(1.4-4.4) 
75,482 
(24,608-212,856) 
139.9 
(45.6-394.4) 
384,620 
(261,428-533,802) 
712.6 
(484.4-989.0) 
Uganda 
468 
(247-795) 
1.2 
(0.6-2.0) 
40,106 
(12,640-115,956) 
102.6 
(32.3-296.7) 
211,795 
(142,907-297,930) 
542.0 
(365.7-762.4) 
Zambia 
187 
(99-314) 
1.1 
(0.6-1.8) 
10,069 
(3,264-28,327) 
58.0 
(18.8-163.1) 
53,609 
(36,587-74,788) 
308.7 
(210.7-430.7) 
Southern Sub-Saharan Africa 
2,335 
(1,496-3,384) 
3.0 
(1.9-4.4) 
155,818 
(56,715-398,658) 
201.4 
(73.3-515.2) 
532,257 
(372,920-726,714) 
687.9 
(482.0-939.2) 
Botswana 
42 
(23-69) 
1.8 
(1.0-3.0) 
3,323 
(1,124-8,928) 
145.6 
(49.3-391.3) 
12,484 
(8,585-17,151) 
547.1 
(376.2-751.6) 
Lesotho 
85 
(43-148) 
4.4 
(2.2-7.6) 
5,261 
(1,772-14,406) 
270.1 
(91.0-739.7) 
18,857 
(12,978-26,135) 
968.2 
(666.4-1,341.9) 
Namibia 
62 
(33-104) 
2.6 
(1.4-4.4) 
5,206 
(1,745-14,313) 
221.2 
(74.1-608.2) 
18,533 
(12,710-25,751) 
787.5 
(540.0-1,094.2) 
South Africa 
1,535 
(990-2,224) 
2.8 
(1.8-4.0) 
107,965 
(39,505-274,607) 
196.5 
(71.9-499.7) 
364,578 
(255,788-497,377) 
663.4 
(465.5-905.1) 
Swaziland 
36 
(18-63) 
3.2 
(1.6-5.6) 
2,672 
(886-7,439) 
237.6 
(78.8-661.6) 
9,907 
(6,787-13,786) 
881.0 
(603.6-1,226.0) 
Zimbabwe 
575 
(298-967) 
3.9 
(2.0-6.6) 
31,285 
(10,509-85,700) 
212.6 
(71.4-582.5) 
107,945 
(73,625-150,724) 
733.6 
(500.4-1,024.4) 
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Western Sub-Saharan Africa 
14,376 
(8,802-21,976) 
3.3 
(2.0-5.1) 
736,346 
(250,820-
1,995,529) 
169.7 
(57.8-460.0) 
2,408,441 
(1,644,131-3,354,242) 
555.2 
(379.0-773.2) 
Benin 
370 
(189-652) 
3.2 
(1.6-5.6) 
19,861 
(6,548-55,124) 
171.4 
(56.5-475.8) 
66,264 
(45,016-92,415) 
572.0 
(388.6-797.7) 
Burkina Faso 
1,021 
(499-1,858) 
4.8 
(2.4-8.8) 
47,655 
(14,626-146,411) 
225.6 
(69.2-693.2) 
150,615 
(95,646-227,206) 
713.1 
(452.8-1,075.7) 
Cameroon 
852 
(439-1,481) 
3.1 
(1.6-5.3) 
50,682 
(16,605-140,926) 
182.5 
(59.8-507.5) 
171,096 
(116,351-238,473) 
616.1 
(419.0-858.8) 
Cape Verde 
14 
(8-23) 
2.6 
(1.5-4.2) 
944 
(327-2,508) 
172.9 
(60.0-459.4) 
3,263 
(2,254-4,483) 
597.8 
(412.9-821.4) 
Chad 
892 
(459-1,519) 
5.9 
(3.0-10.0) 
41,699 
(13,153-118,824) 
273.9 
(86.4-780.6) 
126,017 
(84,702-177,330) 
827.9 
(556.4-1,165.0) 
Cote d'Ivoire 
1,709 
(890-2,979) 
6.8 
(3.6-11.9) 
98,969 
(32,909-273,216) 
396.4 
(131.8-1,094.4) 
326,632 
(222,550-455,363) 
1,308.3 
(891.4-1,824.0) 
The Gambia 
51 
(27-86) 
2.4 
(1.3-4.0) 
3,089 
(1,008-8,780) 
144.9 
(47.2-411.7) 
10,287 
(6,835-14,698) 
482.4 
(320.5-689.2) 
Ghana 
800 
(432-1,328) 
2.6 
(1.4-4.4) 
44,574 
(14,846-124,282) 
147.6 
(49.1-411.5) 
154,614 
(104,240-218,036) 
511.9 
(345.1-721.8) 
Guinea 
588 
(314-992) 
5.0 
(2.7-8.4) 
30,089 
(9,878-83,871) 
254.6 
(83.6-709.6) 
94,097 
(63,799-131,429) 
796.1 
(539.8-1,111.9) 
Guinea-Bissau 
60 
(31-105) 
3.3 
(1.7-5.7) 
3,535 
(1,150-9,878) 
190.5 
(62.0-532.3) 
11,825 
(8,024-16,513) 
637.3 
(432.4-889.9) 
Liberia 
118 
(60-208) 
2.5 
(1.3-4.4) 
10,190 
(3,321-28,509) 
215.8 
(70.3-603.7) 
33,382 
(22,675-46,565) 
706.8 
(480.1-986.0) 
Mali 
520 
(257-933) 
2.6 
(1.3-4.6) 
30,037 
(9,530-85,857) 
148.3 
(47.1-423.9) 
96,525 
(65,376-135,684) 
476.6 
(322.8-669.9) 
Mauritania 
97 
(51-168) 
2.5 
(1.3-4.3) 
7,035 
(2,302-19,768) 
179.7 
(58.8-505.1) 
23,387 
(15,914-32,561) 
597.5 
(406.6-831.9) 
Niger 
929 
(467-1,642) 
4.3 
(2.2-7.7) 
50,113 
(16,111-142,342) 
234.4 
(75.4-665.9) 
154,944 
(104,361-217,665) 
724.9 
(488.2-1,018.3) 
Nigeria 
5,406 
(2,800-9,481) 
2.6 
(1.4-4.6) 
231,464 
(74,522-654,841) 
112.3 
(36.2-317.7) 
758,410 
(511,634-1,063,013) 
368.0 
(248.3-515.8) 
Sao Tome and Principe 
7 
(4-11) 
3.4 
(1.9-5.6) 
459 
(154-1,265) 
229.1 
(77.1-631.8) 
1,624 
(1,111-2,251) 
811.2 
(555.1-1,124.5) 
Senegal 
398 
(210-682) 
2.7 
(1.4-4.6) 
33,572 
(11,066-92,896) 
228.6 
(75.3-632.5) 
105,805 
(71,735-147,803) 
720.3 
(488.4-1,006.3) 
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Location Deaths (95% UI) 
Deaths per 
100,000 (95% UI) 
Hospitalisations 
(95% UI) 
Hospitalisations 
per 100,000 (95% 
UI) Episodes (95% UI) 
Incidence per 
100,000 (95% 
UI) 
Sierra Leone 
346 
(181-601) 
4.4 
(2.3-7.7) 
19,618 
(6,433-54,239) 
250.6 
(82.2-692.7) 
64,288 
(43,636-89,733) 
821.1 
(557.3-1,146.1) 
Togo 
198 
(103-339) 
2.6 
(1.4-4.5) 
14,298 
(4,745-39,440) 
190.2 
(63.1-524.7) 
47,955 
(32,728-66,623) 
638.0 
(435.4-886.4) 
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Figure 1. Conceptual diagram of the influenza LRI burden pyramid 
This diagram shows a spectrum of influenza LRI disease. This manuscript presents estimates of moderate and severe influenza LRI, of which 
some fraction (modeled independently) is hospitalised, and mortality due to influenza LRI. This study did not estimate inapparent infection which 
may be important for understanding influenza LRI transmission dynamics but does not account for a measurable burden of disease. 
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Figure 2. Age distribution of deaths, hospitalisations, and episodes caused by influenza LRI globally in 2017 
EN = early neonatal (0-6 days), LN = late neonatal (7-27 days), PN = post neonatal. Influenza is not attributed to LRI in the early or late neonatal 
age groups.  
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Figure 3. Influenza LRI mortality rate per 100,000 all ages in 2017 
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Figure 4. Influenza LRI hospitalisations per 100,000, all ages in 2017 
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Figure 5. Influenza LRI incidence per 100,000 all ages in 2017 
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